Polystyrene sulphonic acid
Generic name
Polystyrene sulphonic acid
Brand name
ATC Code
V03AE01
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Polystyrene resins are insoluble and are not absorbed.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Hyperkaliaemia; Prevention of hyperkaliaemia in chemotherapy |
|---|
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Constipation. After rectal administration, especially in children: obstruction of the ileus due to clumping of the resin, and of haematochezia in premature babies and neonates with a low birthweight.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications in children
- Oral use in neonates
- Oral and rectal use in premature neonates < 28 weeks GA or in neonates with decreased intestinal activity.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Determine the plasma concentrations of sodium, potassium and calcium regularly. Be aware of the possibility of obstipation. Special care is required when administering rectally to children and neonates, as excessive dosage or inadequate dilution results in impaction of the resin; there is a risk of local haemorrhage or necrosis in premature babies or neonates with low birthweights. After retention of each enema, irrigate the colon well to remove the resin properly. For rectal administration, suspend the powder in 150 ml of a 5% glucose solution; apply a cleansing enema before insertion.
When sodium restriction is indicated, the calcium salt is preferred.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
ALL OTHER THERAPEUTIC PRODUCTS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Antidotes | ||
|---|---|---|
| V03AB27 | ||
| V03AB16 | ||
| V03AB24 | ||
| V03AB25 | ||
| V03AB33 | ||
| V03AB17 | ||
| V03AB15 | ||
| V03AB13 | ||
| V03AB19 | ||
| V03AB14 | ||
| V03AB06 | ||
| V03AB35 | ||
| Iron chelating agents | ||
|---|---|---|
| V03AC03 | ||
| V03AC02 | ||
| V03AC01 | ||
| Drugs for treatment of hyperkalemia and hyperphosphatemia | ||
|---|---|---|
| V03AE07 | ||
| V03AE02 | ||
| V03AE01 | ||
| Detoxifying agents for antineoplastic treatment | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
| V03AF07 | ||
| Drugs for treatment of hypoglycemia | ||
|---|---|---|
| V03AH01 | ||
| Other therapeutic products | ||
|---|---|---|
| V03AX03 | ||
| DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
| V03AF07 | ||
| OTHER THERAPEUTIC PRODUCTS | ||
|---|---|---|
| V03AX03 | ||
References
- Fresenius Medical Care Deutschland GmbH, SPC Sorbisterit (RVG 10261) 13-03-2020, www.geneesmiddeleninformatiebank.nl
- Kamps WA et al, Guidance Supportive Care Pediatric Oncology, VU Uitgeverij,, 2005
- Sanofi-Aventis Netherlands BV, SPC Resonium A (RVG 08071) 26-11-2018, www.geneesmiddeleninformatiebank.nl
- Kamps WA et al, Guidance Supportive Care Pediatric Oncology, VU Uitgeverij,, 2005
Changes
Therapeutic Drug Monitoring
Overdose
